Host, reproductive, and lifestyle factors in relation to quantitative histologic metrics of the normal breast.
Body mass index
Breast cancer
Breast tissue composition
Epithelium
Epithelium-to-stroma proportion
Ethnicity
Etiology
Family history
Normal breast
Parity
Race
Risk factors
Stroma
Journal
Breast cancer research : BCR
ISSN: 1465-542X
Titre abrégé: Breast Cancer Res
Pays: England
ID NLM: 100927353
Informations de publication
Date de publication:
15 08 2023
15 08 2023
Historique:
received:
01
05
2023
accepted:
29
07
2023
medline:
17
8
2023
pubmed:
16
8
2023
entrez:
15
8
2023
Statut:
epublish
Résumé
Emerging data indicate that variations in quantitative epithelial and stromal tissue composition and their relative abundance in benign breast biopsies independently impact risk of future invasive breast cancer. To gain further insights into breast cancer etiopathogenesis, we investigated associations between epidemiological factors and quantitative tissue composition metrics of the normal breast. The study participants were 4108 healthy women ages 18-75 years who voluntarily donated breast tissue to the US-based Susan G. Komen Tissue Bank (KTB; 2008-2019). Using high-accuracy machine learning algorithms, we quantified the percentage of epithelial, stromal, adipose, and fibroglandular tissue, as well as the proportion of fibroglandular tissue that is epithelium relative to stroma (i.e., epithelium-to-stroma proportion, ESP) on digitized hematoxylin and eosin (H&E)-stained normal breast biopsy specimens. Data on epidemiological factors were obtained from participants using a detailed questionnaire administered at the time of tissue donation. Associations between epidemiological factors and square root transformed tissue metrics were investigated using multivariable linear regression models. With increasing age, the amount of stromal, epithelial, and fibroglandular tissue declined and adipose tissue increased, while that of ESP demonstrated a bimodal pattern. Several epidemiological factors were associated with individual tissue composition metrics, impacting ESP as a result. Compared with premenopausal women, postmenopausal women had lower ESP [β (95% Confidence Interval (CI)) = -0.28 (- 0.43, - 0.13); P < 0.001] with ESP peaks at 30-40 years and 60-70 years among pre- and postmenopausal women, respectively. Pregnancy [β (95%CI) Our findings revealed that cumulative exposure to etiological factors over the lifespan impacts normal breast tissue composition metrics, individually or jointly, to alter their dynamic equilibrium, with potential implications for breast cancer susceptibility and tumor etiologic heterogeneity.
Sections du résumé
BACKGROUND
Emerging data indicate that variations in quantitative epithelial and stromal tissue composition and their relative abundance in benign breast biopsies independently impact risk of future invasive breast cancer. To gain further insights into breast cancer etiopathogenesis, we investigated associations between epidemiological factors and quantitative tissue composition metrics of the normal breast.
METHODS
The study participants were 4108 healthy women ages 18-75 years who voluntarily donated breast tissue to the US-based Susan G. Komen Tissue Bank (KTB; 2008-2019). Using high-accuracy machine learning algorithms, we quantified the percentage of epithelial, stromal, adipose, and fibroglandular tissue, as well as the proportion of fibroglandular tissue that is epithelium relative to stroma (i.e., epithelium-to-stroma proportion, ESP) on digitized hematoxylin and eosin (H&E)-stained normal breast biopsy specimens. Data on epidemiological factors were obtained from participants using a detailed questionnaire administered at the time of tissue donation. Associations between epidemiological factors and square root transformed tissue metrics were investigated using multivariable linear regression models.
RESULTS
With increasing age, the amount of stromal, epithelial, and fibroglandular tissue declined and adipose tissue increased, while that of ESP demonstrated a bimodal pattern. Several epidemiological factors were associated with individual tissue composition metrics, impacting ESP as a result. Compared with premenopausal women, postmenopausal women had lower ESP [β (95% Confidence Interval (CI)) = -0.28 (- 0.43, - 0.13); P < 0.001] with ESP peaks at 30-40 years and 60-70 years among pre- and postmenopausal women, respectively. Pregnancy [β (95%CI)
CONCLUSION
Our findings revealed that cumulative exposure to etiological factors over the lifespan impacts normal breast tissue composition metrics, individually or jointly, to alter their dynamic equilibrium, with potential implications for breast cancer susceptibility and tumor etiologic heterogeneity.
Identifiants
pubmed: 37582731
doi: 10.1186/s13058-023-01692-7
pii: 10.1186/s13058-023-01692-7
pmc: PMC10426057
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
97Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Semin Cell Dev Biol. 2010 Feb;21(1):11-8
pubmed: 19857593
Br J Cancer. 2014 Mar 4;110(5):1367-77
pubmed: 24548865
Int J Cancer. 2018 Aug 15;143(4):746-757
pubmed: 29492969
Breast Cancer Res. 2006;8(4):R43
pubmed: 16859501
J Natl Cancer Inst. 2003 Aug 20;95(16):1218-26
pubmed: 12928347
JAMA. 2003 Jun 25;289(24):3243-53
pubmed: 12824205
Breast Cancer Res. 2017 May 25;19(1):61
pubmed: 28545469
Cancer Prev Res (Phila). 2012 Apr;5(4):528-35
pubmed: 22345117
JNCI Cancer Spectr. 2021 Feb 06;5(3):
pubmed: 33981950
Breast Cancer Res Treat. 2016 Aug;159(1):163-72
pubmed: 27488681
J Natl Cancer Inst. 2014 Aug 12;106(8):
pubmed: 25118203
Br J Cancer. 2006 Jul 3;95(1):123-9
pubmed: 16755295
J Natl Cancer Inst. 2022 Oct 6;114(10):1420-1424
pubmed: 35333343
Epidemiology. 1994 Nov;5(6):604-11
pubmed: 7841242
Trends Mol Med. 2009 Jan;15(1):5-13
pubmed: 19091631
Am J Epidemiol. 2011 Mar 1;173(5):509-17
pubmed: 21266505
Cancer Epidemiol Biomarkers Prev. 1998 Sep;7(9):783-9
pubmed: 9752986
Proc Soc Exp Biol Med. 1997 Oct;216(1):28-43
pubmed: 9316608
Mod Pathol. 2018 Jul;31(7):1085-1096
pubmed: 29463881
J Clin Oncol. 2009 Dec 10;27(35):5893-8
pubmed: 19805686
Breast Cancer Res Treat. 2008 May;109(1):123-39
pubmed: 17578664
Br J Cancer. 1960 Sep;14:437-48
pubmed: 13782349
Int J Cancer. 2008 Aug 15;123(4):933-41
pubmed: 18506692
Breast Cancer Res. 2012 Apr 18;14(2):R64
pubmed: 22513288
J Natl Cancer Inst. 1980 Jan;64(1):9-16
pubmed: 6928051
J Natl Cancer Inst. 2014 Sep 15;106(10):
pubmed: 25224496
Cancer Epidemiol Biomarkers Prev. 1999 Oct;8(10):873-9
pubmed: 10548315
JAMA Oncol. 2018 Nov 1;4(11):e181771
pubmed: 29931120
Lancet. 2003 Aug 9;362(9382):419-27
pubmed: 12927427
Am J Epidemiol. 1987 Aug;126(2):319-25
pubmed: 3605058
Breast Cancer Res Treat. 2013 Jan;137(2):579-87
pubmed: 23224237
Breast Cancer Res Treat. 2020 Aug;182(3):555-579
pubmed: 32572713
Breast Cancer Res. 2014 Mar 17;16(2):R26
pubmed: 24636070
Cancer. 2002 Dec 15;95(12):2455-64
pubmed: 12467057
J Natl Cancer Inst. 2014 Oct 01;106(10):
pubmed: 25274491
Obstet Gynecol. 1997 Sep;90(3):453-6
pubmed: 9277661
Acta Oncol. 2018 May;57(5):595-603
pubmed: 29164969
JNCI Cancer Spectr. 2021 Jan 11;5(1):
pubmed: 33644680
NPJ Breast Cancer. 2020 Sep 7;6:41
pubmed: 32964115
Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1558-68
pubmed: 15466970
Nat Rev Cancer. 2006 Apr;6(4):281-91
pubmed: 16557280
Int J Cancer. 1986 Jan 15;37(1):21-5
pubmed: 3941020
Lancet Oncol. 2006 Nov;7(11):910-8
pubmed: 17081916
Cancer Prev Res (Phila). 2011 Jul;4(7):1021-9
pubmed: 21622727
Int J Cancer. 2016 Mar 1;138(5):1094-101
pubmed: 26384849
Am J Pathol. 2006 Feb;168(2):608-20
pubmed: 16436674
Menopause. 2009 May-Jun;16(3):576-81
pubmed: 19169161
Breast Cancer Res Treat. 2012 May;133(1):169-77
pubmed: 21881938
J Natl Cancer Inst. 2008 Dec 17;100(24):1804-14
pubmed: 19066264
BMC Cancer. 2006 Mar 22;6:78
pubmed: 16551373
Ann Intern Med. 2019 Jan 1;170(1):22-30
pubmed: 30534999
Breast Cancer Res Treat. 2018 Aug;170(3):487-497
pubmed: 29603032
Cancer Prev Res (Phila). 2016 Feb;9(2):149-58
pubmed: 26645278
Cancer. 1964 Feb;17:141-51
pubmed: 14123673
Physiol Rev. 1996 Jan;76(1):69-125
pubmed: 8592733
Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1883-91
pubmed: 21846820
Breast Cancer Res Treat. 2020 Jan;179(1):185-195
pubmed: 31535320
JAMA. 2003 Jun 25;289(24):3254-63
pubmed: 12824206
Nat Rev Cancer. 2001 Oct;1(1):46-54
pubmed: 11900251
Cancer Causes Control. 2007 Dec;18(10):1187-98
pubmed: 17823850
J Natl Cancer Inst. 1982 Feb;68(2):211-7
pubmed: 6950154
Breast Cancer Res. 2021 Jul 5;23(1):70
pubmed: 34225771
Pathol Res Pract. 1980;166(4):515-35
pubmed: 6253967
Horm Cancer. 2017 Aug;8(4):211-218
pubmed: 28567703
J Natl Cancer Inst. 2011 Feb 2;103(3):250-63
pubmed: 21191117
J Mammary Gland Biol Neoplasia. 2009 Jun;14(2):87-98
pubmed: 19381788
Mol Endocrinol. 2002 Sep;16(9):2034-51
pubmed: 12198241
Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2482-8
pubmed: 17164374
Breast Cancer Res. 2010;12(3):205
pubmed: 20584344